News, trends, and stories from the synthetic biology industry
Hi ,
Today is the day! For the first time ever, SynBioBeta is hosting a one-day event exclusively focused on the potential of bioengineering in food and agriculture. This is your opportunity to hear from industry experts who are
transforming our food systems through alternative proteins, circular agriculture, gene editing, and more. Register now.
SynBioBeta Food & Ag
Here are some of the sessions that you don't want to miss today at 8 am PST at the Food and Agriculture Conference (Click here to see the schedule).
Maarten Bosch, CEO of Mosa Meat, the European food technology company that introduced the world’s first cultivated beef hamburger in 2013. They recently announced the third and last closing of their Series B funding. This third closing of $10 million brings the total raised in the round to $85 million.
Alejandro Tocigl, CEO of Miroculus, a developer of tools for personal lab automation, which announced the completion of a Series B extension, bringing the total capital raised in the series to $45 million.
Sean McClain, CEO of AbSci, a synthetic biology company that unifies biologic drug discovery and development processes, and recently announced a strategic equity investment by Merck Global Health Innovation Fund (Merck GHI).
CRISPR Clinical Trials: A 2021 Update
2020 was a big year for CRISPR – the discoveries of new Cas proteins, use of CRISPR technology to study and develop diagnostic tests of COVID-19, a Nobel Prize, and more. The past year has also brought results from clinical trials using CRISPR technology and the start of new clinical trials. In this article, IGI will go over the basics of clinical trials and then map out the current CRISPR-based trials from disease background to what we really hope to learn from these trials.
SynBioBeta: In-Depth How Will the Proteins of the Future Be Designed?
One of synthetic biology’s biggest challenges is mastering the art of protein folding and design. Although bioengineering techniques have advanced significantly, synthetic biologists cannot perfectly design a protein’s sequence or shape purely through computer modeling. So what does the future of protein design look like, and how will it change what we can build with biology?
If you missed our first SynBioBeta Live of the year, you can still watch it here! "What does the future of distributed automated research for deep technologies like synthetic biology look like?" was sponsored by our good friends at Strateos.
Why Killing Animals For Meat Could Be A Thing of the Past In the last few months, interest in cultured meat has taken off. Cultured meat heralds a potential breakthrough for food sustainability. Until recently, this novel food was a technological aspiration rather than a reality. But now, cultured chicken nuggets have been approved in Singapore. When will other countries take their first bite?
What Can Synthetic Biology Do Better to Help End Hunger? Public policies are laws and regulations that seek to solve or mitigate public problems, from social inequities and the climate crisis to world
hunger. But how can synthetic biology entrepreneurs use public policy to accelerate ag-tech? What steps do startups need to take to work more synergistically with governments and community leaders? The first step is for scientists, innovators, and policymakers to find a common language.
DNA Script has been selected by GE Research to join a collaboration to develop a rapid response, mobile medical manufacturing platform to enable on-demand production of nucleic acid-based vaccines and therapies. The project was awarded as part of DARPA's Nucleic Acids On-Demand World-Wide (NOW) program, and DNA Script will receive up to $9.35 million.
Future Fields raised $2.2 million and shipped their first cellular meat product. They are developing a first-of-its-kind cellular growth medium that enables customers to create lab-grown meat at a lower cost.
Phenotypeca has successfully raised £300,000 of seed investment. This investment strengthens Phenotypeca’s yeast biofoundry platform, using baker’s yeast for a production strain
optimization service to enable the low-cost manufacture of therapeutic proteins, vaccines and diagnostics.
